Compass Therapeutics (NASDAQ:CMPX) Stock Price Up 4.5% – Should You Buy?

Compass Therapeutics, Inc. (NASDAQ:CMPX) rose 4.5% during mid-day trading on Tuesday . The company traded as high as $5.39 and last traded at $5.38. Approximately 1,662,732 shares traded hands during trading, a decline of 2% from the average daily volume of 1,705,218 shares. The stock had previously closed at $5.15.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on CMPX. Wall Street Zen raised shares of Compass Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Compass Point set a $10.00 target price on Compass Therapeutics in a research report on Monday, October 6th. Cantor Fitzgerald began coverage on Compass Therapeutics in a report on Wednesday, December 3rd. They set an “overweight” rating for the company. Canaccord Genuity Group assumed coverage on Compass Therapeutics in a research note on Wednesday, December 3rd. They issued a “buy” rating and a $10.00 price target for the company. Finally, Citizens Jmp assumed coverage on shares of Compass Therapeutics in a research report on Wednesday, December 3rd. They set a “market outperform” rating and a $10.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $12.23.

Compass Therapeutics Price Performance

The company has a market cap of $956.89 million, a P/E ratio of -11.96 and a beta of 1.44. The stock has a 50-day moving average of $4.81 and a 200 day moving average of $3.78.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. Sell-side analysts predict that Compass Therapeutics, Inc. will post -0.36 EPS for the current year.

Hedge Funds Weigh In On Compass Therapeutics

A number of institutional investors have recently modified their holdings of CMPX. Suvretta Capital Management LLC lifted its position in shares of Compass Therapeutics by 97.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock worth $49,354,000 after buying an additional 6,951,666 shares during the last quarter. Vivo Capital LLC raised its stake in Compass Therapeutics by 57.9% during the third quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock worth $33,409,000 after acquiring an additional 3,502,000 shares in the last quarter. Balyasny Asset Management L.P. bought a new position in shares of Compass Therapeutics in the third quarter worth about $9,892,000. Millennium Management LLC boosted its stake in shares of Compass Therapeutics by 280.4% in the 3rd quarter. Millennium Management LLC now owns 3,237,572 shares of the company’s stock valued at $11,332,000 after purchasing an additional 2,386,367 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Compass Therapeutics by 45.6% in the 3rd quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company’s stock valued at $24,720,000 after purchasing an additional 2,212,794 shares in the last quarter. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.